Literature DB >> 28325601

Design and synthesis of novel 6-aryl substituted 4-anilinequinazoline derivatives as potential PI3Kδ inhibitors.

Minhang Xin1, Yuan-Yuan Hei1, Hao Zhang1, Ying Shen1, San-Qi Zhang2.   

Abstract

In this study, a series of new 6-aryl substituted 4-anilinequinazolines was designed and synthesized as PI3Kδ inhibitors based on our reported chemical structures. The preliminary structure-activity relationship (SAR) was established, and compounds 13h and 13k displayed most potent PI3Kδ inhibitory activities with the IC50 values of 9.3nM and 9.7nM, respectively. Compound 13h demonstrated similar anti-proliferative profiles to idelalisib against three human B cell lines. Three key hydrogen bonding interactions were found in the docking of 13h with PI3Kδ enzyme. These results suggest that compound 13h possessed nanomolar PI3Kδ inhibitory activity and distinctive chemical structure, deserving further structural optimization.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  6-Aryl substituted 4-anilinequinazolines; Drug design; PI3Kδ inhibitors; Structure-activity relationship

Mesh:

Substances:

Year:  2017        PMID: 28325601     DOI: 10.1016/j.bmcl.2017.03.020

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  2 in total

1.  Design, Synthesis and Biological Evaluation of Novel Phenylsulfonylurea Derivatives as PI3K/mTOR Dual Inhibitors.

Authors:  Bingbing Zhao; Fei Lei; Caolin Wang; Binliang Zhang; Zunhua Yang; Wei Li; Wufu Zhu; Shan Xu
Journal:  Molecules       Date:  2018-06-27       Impact factor: 4.411

2.  Introduction of pyrrolidineoxy or piperidineamino group at the 4-position of quinazoline leading to novel quinazoline-based phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.

Authors:  Minhang Xin; Weiming Duan; Yifan Feng; Yuan-Yuan Hei; Hao Zhang; Ying Shen; Hong-Yi Zhao; Shuai Mao; San-Qi Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.